Clinical Trial

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

Active, Not Recruiting Phase 1/2

Summary

This phase I/II trial studies the side effects and best dose of cabazitaxel when given together with enzalutamide in treating patients with prostate cancer that has spread to other places in the body (metastatic) and has not responded to treatment with hormones or no longer responds to treatment with hormones (hormone-resistant). Drugs used in chemotherapy, such as cabazitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Androgen can cause the growth of prostate cancer cells. Hormone therapy using enzalutamide may fight prostate cancer by blocking the use of androgen by the tumor cells. Giving cabazitaxel together with enzalutamide may work better in treating metastatic, hormone-resistant prostate cancer.

Protocol Amendment History 19 amendments

This ClinicalTrials.gov record has been amended 19 times since 2015-08-11; most recent amendment 2026-02-12.

Status change: Recruiting → Active, Not Recruiting 2020-04-23

Trial Details

NCT Number	NCT02522715
Lead Sponsor	OHSU Knight Cancer Institute Collaborators: Oregon Health and Science University
Conditions	Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
Enrollment	37 participants
Start Date	2015-08-13
Primary Completion	2019-10-16 (estimated)
Study Completion	2027-01-01 (estimated)
Updated on ClinicalTrials.gov	2026-02-24